{
    "clinical_study": {
        "@rank": "60453", 
        "arm_group": {
            "arm_group_label": "Melphalan, carmustine, etoposide, cytarabine (BEAM)", 
            "arm_group_type": "Experimental", 
            "description": "Day -7, carmustine intravenous (IV) infusion\nDays -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day\nDay -2, melphalan HCl (propylene glycol-free)(IV) infusion\nDay 0, stem cell transplant."
        }, 
        "brief_summary": {
            "textblock": "Phase II study is being conducted to confirm the safety and efficacy of high-dose Melphalan\n      HCl for Injection (Propylene Glycol-Free) when included in the BEAM regimen for\n      myeloablative conditioning in lymphoma patients undergoing ASCT"
        }, 
        "brief_title": "Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hodgkin Disease", 
            "Lymphoma, Non-Hodgkin"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma.\n\n          -  Eligible for autologous stem cell transplantation.\n\n          -  18 to 75 years of age at time of enrollment.\n\n          -  Adequate autologous graft, defined as an unmanipulated, cryopreserved, peripheral\n             blood stem cell graft containing at least 2 x 10^6 CD34+ cells/kg based on patient\n             body weight\n\n          -  ECOG performance status \u2264 2\n\n          -  Normal organ function as defined below:\n\n               -  Creatinine clearance > 40 ml/min\n\n               -  Total bilirubin \u22642.0 x IULN\n\n               -  AST(SGOT)/ALT(SGPT) \u2264 3.0 x IULN\n\n               -  LVEF > 40% (by ECHO or MUGA)\n\n               -  FEV1 > 50% of predicted and DLCO > 50% of predicted\n\n          -  Women of childbearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control, abstinence) prior to study entry and\n             for the duration of study participation.  Should a woman become pregnant or suspect\n             she is pregnant while participating in this study, she must inform her treating\n             physician immediately.\n\n          -  Able to understand and willing to sign an IRB approved written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  A history of other malignancy \u2264 5 years previous with the exception of basal cell or\n             squamous cell carcinoma of the skin which were treated with local resection only or\n             carcinoma in situ of the cervix.\n\n          -  Currently receiving any other experimental therapy or has received any other\n             experimental therapy within the 4 weeks prior to enrollment.\n\n          -  A history of allergic reactions attributed to compounds of similar chemical or\n             biologic composition to melphalan HCl for injection (propylene glycol-free),\n             Captisol, or other agents used in the study.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, unstable\n             cardiac arrhythmias, or psychiatric illness/social situations that would limit\n             compliance with study requirements.\n\n          -  Pregnant and/or breastfeeding women.  Women of childbearing potential must have a\n             negative serum pregnancy test within 14 days of study entry.\n\n          -  Known HIV-positivity. These patients are excluded because of the potential for\n             pharmacokinetic interactions with the study regimen and their antiretroviral therapy\n             and because these patients are at increased risk of lethal infections when treated\n             with marrow-suppressive therapy.  .\n\n          -  Inclusion of Women and Minorities\n\n        Both men and women and members of all races and ethnic groups are eligible for this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969435", 
            "org_study_id": "201312115"
        }, 
        "intervention": [
            {
                "arm_group_label": "Melphalan, carmustine, etoposide, cytarabine (BEAM)", 
                "intervention_name": "Carmustine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BCNU", 
                    "BiCNU\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Melphalan, carmustine, etoposide, cytarabine (BEAM)", 
                "intervention_name": "Etoposide phosphate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "VP-16", 
                    "Vepesid"
                ]
            }, 
            {
                "arm_group_label": "Melphalan, carmustine, etoposide, cytarabine (BEAM)", 
                "intervention_name": "Cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cytosar-U \u00ae", 
                    "1-\u03b2-Arabinofuranosylcytosine", 
                    "Arabinosylcytosine", 
                    "Cytosine arabinoside", 
                    "Ara-C"
                ]
            }, 
            {
                "arm_group_label": "Melphalan, carmustine, etoposide, cytarabine (BEAM)", 
                "intervention_name": "Melphalan HCl (propylene glycol-free)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carmustine", 
                "Melphalan", 
                "Etoposide phosphate", 
                "Cytarabine", 
                "Etoposide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 2, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "acashen@dom.wustl.edu", 
                "last_name": "Amanda Cashen, M.D.", 
                "phone": "314-454-8304"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Camille Abboud, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John DiPersio, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Todd Fehniger, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Timothy Graubert, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Meagan Jacoby, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Iskra Pusic, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rizwan Romee, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mark Schroeder, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Keith Stockerl-Goldstein, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Tomasson, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Geoffrey Uy, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ravi Vij, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Matthew Walter, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lukas Wartman, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Welch, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Peter Westervelt, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tanya Wildes, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Melphalan HCl for Injection (Propylene Glycol-free), Combined With Carmustine, Etoposide, and Cytarabine (BEAM Regimen) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation", 
        "overall_contact": {
            "email": "acashen@dom.wustl.edu", 
            "last_name": "Amanda Cashen, M.D.", 
            "phone": "314-454-8304"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Amanda Cashen, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The number and percentage of patients who experienced grade 3-5 non-hematologic adverse events.  Adverse events will be assessed using the National Cancer Institute (NCI)-CTCAE version 4.0.", 
                "measure": "Safety and Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "100 days"
            }, 
            {
                "description": "TRM is defined as death not due to progressive lymphoma prior to Day 100 after transplant", 
                "measure": "Treatment-related mortality (TRM)", 
                "safety_issue": "Yes", 
                "time_frame": "100 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969435"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The response rates according to each category of response Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD) will be summarized by the proportion (with 95% confidence intervals) of patients meeting each criterion.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "For patients with CR at day +100. Proportion of patients who survive without any signs or symptoms of cancer at 1 year. Summarized by the proportion (with 95% confidence intervals).", 
                "measure": "1-year Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 1 year"
            }, 
            {
                "description": "For patients with CR at day +100. Proportion of patients who survive without any signs or symptoms of cancer at 2 years. Summarized by the proportion (with 95% confidence intervals).", 
                "measure": "2-year Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "Assessed at 2 years"
            }, 
            {
                "description": "Time from the date of the transplant to the date of neutrophil engraftment. Calculated for each patient and summarized using Kaplan-Meier estimates.", 
                "measure": "Time to engraftment (neutrophil)", 
                "safety_issue": "No", 
                "time_frame": "Assessed up to day 30"
            }, 
            {
                "description": "Time from the date of transplant to the date of platelet engraftment. Calculated for each patient and summarized using Kaplan-Meier estimates.", 
                "measure": "Time to engraftment (platelet)", 
                "safety_issue": "No", 
                "time_frame": "Assessed up to day 100"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}